Market Place
Sourcing Support
Pfizer tabs controversial Chinese firm Huahai to make Paxlovid
24 Aug 2022 //
FIERCEPHARMA
Pfizer Picks China Firm Involved in Drug Recall for Covid Pill
23 Aug 2022 //
BLOOMBERG
Biocon-Viatris, AstraZeneca, Huhai and more—Fierce Pharma Asia
19 Nov 2021 //
FIERCEPHARMA
Valsartan recall protagonist comes off FDA warning letter
16 Nov 2021 //
FIERCEPHARMA
Zhejiang Huahai Pharma Receives FDA Warning Letter
11 Nov 2021 //
FDA
EMA, FDA begin reviewing heartburn medicines for carcinogen
17 Sep 2019 //
ENDPTS
US officials worried about Chinese control of American drug supply
13 Sep 2019 //
NBCNEWS
EMA, FDA Begin Reviewing Heartburn Medicines for Carcinogen
13 Sep 2019 //
RAPS
NDEA & NDMA Impurities: Another Indian Manuf. Receives an FDA Warning Letter
13 Aug 2019 //
RAPS
Fourth Carcinogen Discovered in Heart Pills Used by Millions
19 Jun 2019 //
BLOOMBERG
Teva recall: Tainted blood pressure drugs continue to show up in U.S. supply
14 Jun 2019 //
FIERCE PHARMA
EMA Urges Pioglitazone Manufacturers to Check for Nitrosamine Impurities
26 Apr 2019 //
RAPS
Heart Drugs Free From Carcinogens Identified as Recalls Drag On
05 Apr 2019 //
BLOOMBERG
FDA`s Gottlieb defends agency response to valsartan contamination
22 Mar 2019 //
BIOPHARMA DIVE
To Prevent Losartan Shortages, FDA Allows Higher Impurity Levels
22 Mar 2019 //
RAPS
FDA updates on recalls of valsartan, losartan and irbesartan
20 Mar 2019 //
FDA
Pfizer Japan recalls high blood pressure drug over cancer-causing impurity
09 Feb 2019 //
REUTERS
Enforcement Report - Week of February 6, 2019
06 Feb 2019 //
FDA
Sartan medicines: companies to review mfg to avoid nitrosamine impurities
01 Feb 2019 //
EMA
FDA moving to `risk-based` inspections even as valsartan scare adds new wrinkle to oversight
31 Jan 2019 //
FIERCE PHARMA
How a Tainted Heart Drug Made in China Slipped Past the FDA
30 Jan 2019 //
BLOOMBERG
Irbesartan distributed by Solco Healthcare voluntarily recalled
19 Jan 2019 //
FDA
Update on the review of CEP applications for sartans (18 Jan 2019)
18 Jan 2019 //
EDQM
Blood pressure drug recall: FDA investigates foreign manufacturers
14 Jan 2019 //
USA TODAY
A wave of drug recalls hits Indian pharma firms in US
09 Jan 2019 //
DNA INDIA
FDA issues alert, voluntary recall on cardiovascular medication
28 Dec 2018 //
MASSACHUSETTS LIVE
Valsartan shows manufacturing pros still have things to learn
21 Dec 2018 //
FIERCE PHARMA
Zhejiang Huahai lambasted in FDA warning for putting profits ahead of safety
12 Dec 2018 //
FIERCE PHARMA
FDA warns API manufacturer involved in valsartan recall
12 Dec 2018 //
FDA
Mylan to recall all batches of blood pressure medicine valsartan in U.S.
05 Dec 2018 //
REUTERS
Valsartan recall expands to Mylan, Teva products
29 Nov 2018 //
FIERCE PHARMA
Mylan recalls batches of blood pressure medicine in U.S.
22 Nov 2018 //
REUTERS
EU cracks down on blood pressure medicine made by Mylan
20 Nov 2018 //
REUTERS
EMA Warns of Impurity in Valsartan From Mylan
20 Nov 2018 //
RAPS
Sandoz recalls losartan products that contain impurity
12 Nov 2018 //
FIERCE PHARMA
FDA updates on angiotensin II receptor blocker (ARB) recalls
09 Nov 2018 //
FDA
Sandoz Recalls Losartan Potassium & Hydrochlorothiazide Due to Trace NDEA
09 Nov 2018 //
FDA
FDA Alerts to Recalls Over Non-Valsartan Product Found to Contain Impurities
02 Nov 2018 //
RAPS
FDA warns some irbesartan tablets in U.S. contain impurity
01 Nov 2018 //
FIERCE PHARMA
The FDA again adds more drugs to its valsartan recall list
25 Oct 2018 //
CNN
EMA places Zhejiang Huahai under ‘increased supervision’ over quality issues
17 Oct 2018 //
IN-PHARMATECHNOLOGY
EMA Sartan Investigation Flags Aurobindo Pharma, Raises ZHP Oversight
16 Oct 2018 //
RAPS
Embattled Chinese drug maker to get $43 million in government support
15 Oct 2018 //
CHINA TODAY ONLINE
EU authorities take further action in ongoing review of sartans
15 Oct 2018 //
EMA
FDA corrects previous word on Huahai import ban
12 Oct 2018 //
FIERCE PHARMA
FDA releases method for detection and quantification of both NDMA and NDEA
12 Oct 2018 //
FDA
Litigation teaches Chinese valsartan maker the downside of U.S. market
10 Oct 2018 //
FIERCE PHARMA
Health Canada finds Zhejiang Huahai Pharmaceuticals site non-compliant with GMP
03 Oct 2018 //
HEALTH CANADA
EU, US Ban Manufacturer use of Valsartan From China’s Zhejiang Huahai
29 Sep 2018 //
RAPS
FDA halts imports from China`s Huahai after heart drug recall
29 Sep 2018 //
REUTERS
Zhejiang Huahai Pharmaceutical Fails EDQM Inspection
29 Sep 2018 //
EDQM
Zhejiang Huahai Pharmaceutical is on FDA Import Alert List
28 Sep 2018 //
FDA
EMA review of impurities in sartan medicines
22 Sep 2018 //
PRESS RELEASE
EMA Extends Valsartan Review to Include Four More Active Substances
22 Sep 2018 //
RAPS
FDA berates Chinese drugmaker tied to global valsartan recall
22 Sep 2018 //
FIERCE PHARMA
Third Form 483 Surfaces for China Company at Center of Valsartan Contamination
21 Sep 2018 //
RAPS
